通过双特异性抗体成功向多抗药性瘤

Raffaella Briante1, Qianting Zhai2, Suchismita Mohanty3

  • 1Antibody Engineering, Kenjockety Biotechnology Inc, Tiburon, CA, USA.

mAbs
|April 18, 2025
PubMed
概括

新的双特异性抗体 (BsAbs) 针对多耐药 (MDR) 癌细胞的P-glycoprotein (P-gp) 和CD47,恢复化疗敏感性,并提供强大的抗瘤效应,降低毒性.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K